Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Global Oil Traders Fuel Kineta’s Drug Pipeline

Published: Wednesday, May 22, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Kineta, Inc. and Hydra, LLC announced the completion of a major investment to add funding to Kineta’s clinical-stage drug programs.

The investment is directed at Kineta’s two lead drug programs - ShK-186, a novel immune-sparing targeted therapeutic focused on autoimmune diseases, and rOAS, a novel pan-viral therapeutic aimed at an array of high-priority contagious pathogens for which there are few effective therapies.

“We are genuinely impressed with Kineta’s leadership and laser-focus on delivering high-caliber R&D to larger global pharmaceutical companies. This is a nimble organization with a track record of development success. Kineta has created a unique, cost-efficient and rational way to move early-stage drug programs into human subjects with a focus on rapidly delivering liquidity. All of these factors went into our investment decision,” explained Jamie Browne, a managing director of Hydra, LLC.

Mr. Browne co-leads Hydra, LLC, along with Ken Backes. Hydra is comprised of 13 recently retired Glencore Ltd. traders. Each Hydra member has committed considerable capital to the new private equity partnership. Hydra is focused on diversified opportunities, including choosing to provide Kineta, Inc., significant funding to make major clinical advancements in two drug development programs.

“Kineta is very pleased to welcome Hydra as a major investor into our clinical-stage programs. This is a team of highly astute investors with broad appreciation for underlying market forces across economic sectors. Their investment is a tremendous vote of confidence for the Kineta model and will enable us to advance our clinical work for two very promising drug candidates,” said Kineta, Inc., President and CEO Charles Magness, Ph.D.

Kineta’s lead program, Shk-186, recently completed phase one studies, successfully positioning it for multiple development pathways for autoimmune diseases. Kineta’s second program, rOAS, is scheduled to enter first-in-human clinical trials later this year. Kineta’s pipeline also contains three additional drug and vaccine adjuvant programs; all have novel mechanisms of action and are aimed at large, global unmet medical needs. Kineta has raised more than $46M since 2008 through grants and private investment. Kineta’s chief business goal is to partner or license clinically validated assets that have achieved pre-specified development milestones to pharmaceutical companies for further clinical development.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!